Abstract
Understanding the mortality impact of COVID-19 requires not only counting the dead, but analyzing how premature the deaths are. We calculate years of life lost (YLL) across 42 countries due to COVID-19 attributable deaths, and also conduct an analysis based on estimated excess deaths. As of June 13th 2020, YLL in heavily affected countries are 2 to 6 times the average seasonal influenza; over two thirds of the YLL result from deaths in ages below 75 and one quarter from deaths below 55; and men have lost 47% more life years than women. The results confirm the large mortality impact of COVID-19 among the elderly. They also call for heightened awareness in devising policies that protect vulnerable demographics losing the largest number of life-years.
One Sentence Summary Across 42 countries, the years of life lost due to COVID-19 are up to 6 times that of the average seasonal flu.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research funding included grant LCF/PR/GN12/50250002 from La Caixa Foundation for Hector Pifarre i Arolas and Guillem Lopez Casasnovas. CN is supported by the University of Oxford's COVID-19 Research Response Fund, number 0009139. The views expressed are those of the author and not necessarily those of the University of Oxford.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used were from publicly available databases, with no need for IRB approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and all analyses are available and reproducible one the OSF repository: https://osf.io/5j9nc/?view_only=48f0f69952814e3a8e967370e7b50954
https://osf.io/5j9nc/?view_only=48f0f69952814e3a8e967370e7b50954
